Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400279 | 1.00 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL12292171 | 1.00 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL12644487 | 1.00 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL12714718 | 1.00 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL31520526 | 1.00 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL19426813 | 0.88 | KMT2A (0.60) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL31135499 | 0.88 | KMT2A (0.60) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL20912321 | 0.88 | KMT2A (0.53) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL30293175 | 0.88 | KMT2A (0.60) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL6326089 | 0.88 | KMT2A (0.53) | KMT2ACASP3EPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025019172-A1 | ANTIMICROBIAL EXTRACTANT FORMED FROM COPPER-CONTAINING SOURCE | CORNING INCORPORATED (US) | 2025-01-23 | — | — | WO | claimed |
| EP-4146249-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | Neuland Laboratories Ltd (IN) | 2023-03-15 | — | — | EP | claimed |
| EP-4732286-A2 | COMPOSITIONS AND METHODS FOR ENCRYPTING, STORING, AND DECRYPTING INFORMATION IN OLIGOMERS | Board of Regents, The University of Texas System (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025058677-A2 | COMPOSITIONS AND METHODS FOR ENCRYPTING, STORING, AND DECRYPTING INFORMATION IN OLIGOMERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025019172-A1 | ANTIMICROBIAL EXTRACTANT FORMED FROM COPPER-CONTAINING SOURCE | CORNING INCORPORATED (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-118165002-A | Polycyclic compounds and methods of use thereof | 桑诺维恩药品公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3252057-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-3565815-B1 | COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS | FOCHON PHARMACEUTICALS LTD (CN) | 2024-03-13 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023039068-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PEPTIDE NUCLEIC ACID INTERMEDIATES | NEUBASE THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| EP-4146249-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | Neuland Laboratories Ltd (IN) | 2023-03-15 | — | — | EP | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | KMT2A 2379/4885CASP3 821/4885EPHX2 671/4885 |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | KMT2A 2379/4885CASP3 821/4885EPHX2 671/4885 |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SLC6A3, SLC6A11, SLC6A13 | KMT2A 2581/4885CASP3 2131/4885EPHX2 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.